Development, Deployment, and Implementation of a Machine Learning Surgical Case Length Prediction Model and Prospective Evaluation.

I am a surgeon with interest in immune management of transplant recipients. I am particularly interested in therapies that influence T cell costimulation pathways and adjuvant therapies that facilitate costimulation blockade to prevent the rejection of transplanted organs without undue suppression of protective immunity. I am also interested in understanding how injury, such as that occurring during trauma or in elective surgery, influences immune responses and subsequent healing following injury.

I am a Surgical Oncologist with clinical and research training in pancreatic and hepatobiliary malignancy.  In 2018, I joined Duke University as the Chief of Surgical Oncology, and the Chief of Surgery in the Duke Cancer Institute.  Previously, I led the clinical and research efforts regarding pancreatic neoplasia within the Department of Surgery at Memorial Sloan Kettering Cancer Center, and served as the Associate Director for Clinical Programs within the David Rubenstein Center for Pancreatic Cancer Research. I also held the Murray F. Brennan endowed Chair in Surgery. 

Over the previous ten years, I have been interested in the progression of pancreatic precursor lesions called intraductal papillary mucinous neoplasms (IPMN).  These cystic precursor lesions of the pancreas present an opportunity for to both study cancer progression, and potentially prevent the development of this lethal malignancy.  My research has focused on biomarker development to identify high-risk IPMN as well as studies evaluating the cause of this disease process.  I have successfully completed phase II and phase III clinical trials in patients with pancreatic cancer and IPMN, and am currently the PI of a first-in-human multi-center randomized chemoprevention trial for pancreatic cancer that is targeting patients with high-risk IPMN.

My laboratory includes both pre and postdoctoral trainees, and they play a critical role in the development of our pancreatic cancer prevention program. 

Dr. Buckland is an Attending Physician at Duke University Hospital Emergency Department. He is the Director of the Duke Acute Care Technology Lab where he leads research in developing technology for the diagnosis and treatment of acute disease in data science and robotics projects by managing collaborative research projects between clinicians and engineers. His work at involves studying how advancements in autonomy impact safety critical systems, including the healthcare system. As part of his focus on autonomy, he is the Medical Director of the the Laboratory for Transformational Administration (LTA) an Operational Data Science group in the Duke Department of Surgery.
In addition, Dr. Buckland is the Deputy Chair of the Human System Risk Board of the Office of the Chief Health and Medical Officer via an Intergovernmental Personnel Act agreement with NASA, where he determines the human system risk of spaceflight and how standards, countermeasures, and mission design can mitigate risk.